



Vivoryon Therapeutics N.V. to Present at Upcoming Conferences

Halle (Saale) / Munich, Germany, November 3, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (**Vivoryon**), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that the Company's management will participate in the following medical and investor conferences in November:

American Society of Nephrology (ASN) Kidney Week 2025

Date: November 5 – 9, 2025

Location: Houston, TX, USA

Title: *"Correlation of eGFR and pE-CCL2 in Older Adult Patients Treated with Varoglutamstat: Data from VIVIAD, a Phase 2B Randomized Clinical Trial"*

Presentation Time: Thursday, November 6, 10:00 am – 12:00 pm CST / 5:00 pm - 7:00 pm CET

Session: Late-Breaking Research Posters

Abstract number/poster details: TH-PO1206

Attendees: Michael Schaeffer, PhD, CBO; Julia Neugebauer, PhD, COO

Link to conference: [American Society of Nephrology | Kidney Week - Annual Meeting \(2025\)](#)

1x1 meetings around the Jefferies Global Healthcare Conference

Date: November 18 – 20, 2025

Location: London, UK

Attendees: Frank Weber, MD, CEO; Julia Neugebauer, PhD, COO

To meet the team contact: IR@vivoryon.com

Deutsches Eigenkapitalforum

Date: November 24 – 26, 2025

Location: Frankfurt/M, Germany

Attendee: Julia Neugebauer, PhD, COO

Link to conference: [Deutsches Eigenkapitalforum](#)

###

About Vivoryon Therapeutics N.V.

Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon's most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease. www.vivoryon.com



Vivoryon Forward Looking Statements

This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of Vivoryon Therapeutics N.V. (the “Company”), estimates and projections with respect to the market for the Company’s products and forecasts and statements as to when the Company’s products may be available. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management’s current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. The Company’s results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company’s future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law.

For more information, please contact:

Investor Contact

Vivoryon Therapeutics N.V.

Dr. Manuela Bader, Director IR & Communication

Email: IR@vivoryon.com

LifeSci Advisors

Sandya von der Weid

Tel: +41 78 680 05 38

Email: svonderweid@lifesciadvisors.com

Media Contact

Trophic Communications

Valeria Fisher or Verena Schossmann

Tel: +49 175 8041816 / +49 151 219 412 77

Email: vivoryon@trophic.eu